Chronic Therapies Drive 10% Growth in Indian Pharma Market

Long-term health management products, specifically chronic therapies, have been driving the growth of the Indian Pharmaceutical Market (IPM) with a 10% increase, in contrast to acute therapies which saw a 2% growth, showing a trend towards prolonged health care solutions. Strong innovation and introducing new products in the industry also helped drive growth.

The Total Sales Audit (TSA) and Secondary Sales Audit (SSA) numbers indicate the market is consistently growing. TSA for the fiscal year ending in October 2024 amounted to Rs 226,217 Cr, showing a 6.8% increase, while SSA was at Rs 190,940 Cr, with a growth rate of 6.7%. During October, TSA was worth Rs 19,957 Cr, showing a 5.0% growth, while SSA was valued at Rs 16,843 Cr, indicating a 4.5% rise from the previous year.

Medical fields like cardiovascular care and diabetes treatment played a significant role in driving the market's growth. The use of medications such as Sacubitril + Valsartan provided a boost to cardiac care, showing notable progress. Similarly, the sales of Glimepiride + Metformin in the anti-diabetic sector amounted to Rs 291 Cr. Gastrointestinal treatments also did well, with Esomeprazole + Domperidone experiencing a significant increase of 29%. Conversely, most subcategories of respiratory and pain therapies experienced decreases, except for certain combinations like Formoterol + Budesonide, which remained stable.

Leading brands demonstrated remarkable increases in sales. Foracort maintained its top spot, starting with Rs 75 Cr in October 2024. Pan-D had a remarkable 20% growth, solidifying its position in the top 10, while Influvac saw an impressive 89% growth, moving up 29 spots.